---
title: "Cytokinetics Announces Positive Topline Results From Acacia-Hcm, The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Non-Obstructive Hypertrophic Cardiomyopathy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285199250.md"
datetime: "2026-05-05T11:44:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285199250.md)
  - [en](https://longbridge.com/en/news/285199250.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285199250.md)
---

# Cytokinetics Announces Positive Topline Results From Acacia-Hcm, The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Non-Obstructive Hypertrophic Cardiomyopathy

May 5 (Reuters) - Cytokinetics Inc (CYTK.O) : \* CYTOKINETICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ACACIA-HCM, THE PIVOTAL PHASE 3 CLINICAL TRIAL OF AFICAMTEN IN PATIENTS WITH NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY \* CYTOKINETICS INC - ACACIA-HCM MEETS DUAL PRIMARY ENDPOINTS IN KCCQ-CSS AND MAXIMAL EXERCISE PERFORMANCE AT WEEK 36 \* CYTOKINETICS INC - NO NEW SAFETY SIGNALS IDENTIFIED; COMPLETION RATES SIMILAR FOR AFICAMTEN AND PLACEBO Source text: Further company coverage: (CYTK.O)

### Related Stocks

- [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [TRI.US](https://longbridge.com/en/quote/TRI.US.md)

## Related News & Research

- [Cytokinetics wins UK approval, NICE backing for heart disease drug](https://longbridge.com/en/news/294347281.md)
- [Cytokinetics CEO Robert I. Blum disposes of 7,500 common shares for $606,525](https://longbridge.com/en/news/293972048.md)
- [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md)
- [Cytokinetics releases ESC 2026 late-breaking abstracts update](https://longbridge.com/en/news/291924960.md)
- [Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $282,065](https://longbridge.com/en/news/293661061.md)